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Summary
Background: Clonogenic tumor cells in the hematopoietic
progenitor cell harvest may contribute to relapse after high
dose therapy for B-cell malignancies. Purging of the HPC
harvest requires large amounts of anti-B-cell antibodies, where-
as CD34-selection enriches self renewing HPC's but malignant
cells are still detectable in many CD34+ fractions.
Patients and methods: We examined the feasability and
safety of a CD34-selection followed by purging with anti-B-
cell antibodies in 11 patients with B-cell non-Hodgkin's lym-
phomas undergoing high-dose therapy with cyclophospha-
mide, BCNU and etoposide with retransfusion of autologous
HPC's.
Results: A mean number of 340 x 108 mononuclear cells
was used for CD34-selection and immunomagnetic purging.
CD34+ cells were enriched from a mean of 1.7% (range 0.2%-
4.5%) to a mean of 68% (range 49%-87%) with a mean recovery
of 27% (range 15%—43%). The mean number of retransfused
CD34+ cells was 1.2 x 106/kg (range 0.6-2.2 x 106/kg) body
weight with a median of 11 days (range 10-13 days) to neutrophil
recovery of 0.5 x 109/l and 17 days (range 13-25 days) to platelet
recovery of 50 x 109/l. Mean number of intravenous antibiotics
and inpatient days were 8 (range 0-14) and 22 (range 19-26)
respectively. Major toxicity consisted in four septicemias.
Conclusions: CD34-selected and purged HPC's are safe
and mediate rapid hematological recovery after high dose
therapy for B-cell non-Hodgkin's lymphomas.
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Introduction
Several lines of evidence suggest that contaminating tu-
mor cells in the HPC harvest may contribute to relapse
after high dose therapy with autologous transplantation
in patients with lymphoid malignancies. Studies at the
University of Nebraska have shown that patients who
are reinfused with morphologically normal bone mar-
row containing clonogenic lymphoma cells have an in-
creased incidence of relapse [1]. In addition, patients
whose bone marrow contains PCR-detectable lympho-
ma cells after immunologic purging have an increased
incidence of relapse after autologous bone marrow trans-
plantation [2, 3]. Moreover, gene marking studies have
demonstrated that marked autologous marrow cells may
be detected at the time of relapse, suggesting that re-
infused tumor cells after high dose therapy contribute to
relapse [4, 5].
Among the methods available to remove residual
lymphoma cell from the HPC harvest of patients with
B-cell malignancies, immunopurging has the advantage
of targeting B cells while sparing normal HPC's. At
present, most centers prefer mobilized peripheral HPC
harvests where the number of nucleated cells is at least
twice as large than in bone marrow harvests. Thus,
purging requires large amounts of antibodies and immu-
nomagnetic beads, making the process cumbersome and
costly.
The identification of the CD34 antigen, expressed on
HPC's but not on lymphoid malignancies, made it pos-
sible to remove residual lymphoma cells by positively
selecting the population containing the bone marrow
repopulating cells. Selection of CD34+ cells from the
HPC harvest results in a one to four log depletion of
contaminating tumor cells, but malignant cells are still
detectable in the CD34-selected fraction of many pa-
tients [6-8]. We have recently demonstrated that the
majority of patients with t(14;18)+ lymphomas still have
a considerable number of contaminating lymphoma
cells after selection of CD34+ HPC's [9]. This finding
may be due to contaminating lymphoma cells not re-
moved through the CD34-selection or to the co-selec-
tion of lymphoma cell progenitors expressing the CD34
antigen [10].
The ability to purify cell fractions enables us to tailor
autografts with the aim to enhance their therapeutic
benefit and to improve disease-free survival. Therefore,
we hypothesized that the combination of a positive selec-
tion of CD34+ HPC's followed by a negative selection
with anti B-cell antibodies coated immunobeads would
result in an optimal depletion of residual lymphoma
cells. We thus examined the feasability of such an ap-
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proach with regard to safety and hematopoietic recovery
in patients with B-cell non-Hodgkin's lymphomas under-
going high-dose therapy with retransfusion of autologous
HPC's.
Patients and methods
Patients and clinical samples
Eligibility criteria regarding high-dose therapy with autologous HPC
transplantation for patients with B-cell non-Hodgkin's lymphomas
were: 1) relapsed chemosensitive follicular lymphoma with or without
transformation (n = 6), 2) relapsed chemosensitive large cell lympho-
ma (« = 1), or 3) first remission of a stage III or IV large cell or
Burkitt's lymphoma with elevated LDH and/or tumor bulk at presen-
tation {n = 4) [11]. Chemosensitivity was determined such that the
largest nodal mass was less then 5 cm and the bone marrow was
infiltrated with less than 20% of the intertrabecular space after induc-
tion or salvage therapy. The protocol was approved by the University
Hospital ethical committee and informed consent was obtained from
each patient.
Collection and processing of mobilized peripheral blood HPC's
Peripheral blood cells were mobilized with cyclophosphamide 1.5 g/m2
in four patients, 2 g/m2 in two patients and 3 g/m2 in five patients.
Granulocyte-colony-stimulating factor (G-CSF) was given at 10 ug/
kg/day as a subcutaneous injection beginning five days after chemo-
therapy until the last day of leukapheresis. Patient underwent apheresis
using a Fenwal CS3000 Plus blood cell separator (Baxter Fenwal,
Deerfield, IL). Three aphereses were performed. Two aphereses were
used to select CD34+ cells, whereas an additional apheresis was
cryopreserved as unmanipulated backup.
Selection of CD34+ cells
Mononuclear cells were incubated for 25 minutes at room temperature
with 20 |ig/ml of biotinylated anti-CD34 monoclonal antibodies
(moAbs) in 150 ml of phosphate-buffered saline (PBS) containing
0.1% human serum albumin (HSA). Treated cells were washed twice
with PBS to remove unbound antibody, diluted in 300 ml PBS/1%
HSA and passed over the Ceprate SC Stem Cell Concentrator (Cell
Pro, Inc, Bothell, WA), containing a sterile column of avidin-coated
polyacrylamide beads. After washing with 300 ml of PBS, CD34+ cells
were removed from the beads by mechanical agitation and eluted with
90 ml PBS with 5% HSA. CD34-selected cells were centrifuged at
400 x
 g at 4°C and resuspended in 32 ml PBS/1% HSA/0.5%
immunoglobulin (Sandoglobulin, Sandoz, Bern).
Immunomagnetic purging of CD34-selected HPC's
Dynal paramagnetic beads (one vial GMP grade Dynabeads M-450
sheep anti-Mouse IgG, Baxter. Maurepas, France) were washed three
times with PBS with 1% HSA and 5% citric acid 38 mM, sodium
citrate 74.8 mM, glucose 123.6 mM (PBS/1%HSA/5%ACD-A) and
resuspended in 9 ml PBS/1%HSA/5%ACD-A. 0.5 mg of each murine
anti-human-CDIO, -CD19 and -CD20 moAbs (all from Baxter, Un-
terschleissheim, Germany) were added and incubated for two to six
hours at 4 "C under continous mixing. Dynabeads were then washed
three times with PBS/1% HSA/5% ACD-A to remove unbound anti-
bodies. CD34-selected cells, resuspended in 32 ml PBS-HSA with 0.5%
immunoglobulin, were injected with antibody-coated dynabeads in 10
ml PBS/1% HSA/5% ACD-A in an Isolex 50 magnetic cell separator
disposable set (Baxter, Fenwal Division, Deerfield, IL) and incubated
at 4=C for one hour using slow end-over-end rotation. Magnetic
separation of rosetted cells was performed using the Isolex 50 Mag-
netic Cell Separator. Unrosetted cells were drained out of the chamber
while the bead/cell fraction (CD10+/CD19+/CD20+ cells) was re-
tained in the Isolex chamber. The rosetted cell fraction was washed
once with 50 ml PBS/1% HSA/5% ACD-A to remove non-rosetted
cells trapped in the bead/cell fraction. Unrosetted cells were centri-
fuged at 400 x g for 15 minutes to remove excess antibodies. The pellet
was resuspended in PBS with heparin, 0.5% HSA and 10% DMSO at a
cell concentration of 20 x 106 cell/ml, cryopreserved using a con-
trolled-rate freezing method and stored at -196°C until further use.
High-dose chemotherapy and retransfusion of CD34-selected and
immunomagneticallv purged HPC's
High-dose chemotherapy consisted of cyclophosphamide 1500 mg/m2/
day by continous intravenous infusion on days -7 to -4, BCNU 300
mg/m2 by intravenous bolus infusion on day -7, and etoposide 300
mg/m2/day in two divided intravenous short term infusions on days -7
to -5 . Retransfusion of CD34-selected and immunopurged cells was
performed on day 0. G-CSF at 5 ug/kg/day subcutaneously was started
on day +1 and administered until the neutrophil count was > 1 x 1O9/1
for three days. Supportive care was given as previously published [11].
Results
Positive selection of CD 34+ HPC's followed by negative
selection of B-cells through immunomagnetic bead
depletion with moAbs
CD34+ cells were selected from two pooled aphereses
using a CellPro immunoadsorption column. The total
number of mononuclear cells loaded on the column, the
percentage of CD34+ cells in the HPC harvest and in
the CD34-selected and immunomagnetically purged cell
fractions, as well as the recovery of CD34+ cells after
CD34-selection and immunomagnetic purging are sum-
marized in Table 1. HPC harvests of three patients (Nos.
1, 3 and 4) were purged with anti-CD19 and anti-CD20
Table 1. Purity, recovery and yield of CD34+ cells after CD34-
selection and after immunopurging.
PIN
1
2
3
4
5
6
7
8
9
10
11
CD34+ cells (%)/total
MNC x 108
In the pro-
genitor cell
harvest
2.7/160
1.8/270
0.5/710
0.2/870
1.1/240
1.4/340
4.5/140
1 3/180
1.1/440
1.5/330
2.8/110
After
CD34-
selection
and purging
84/1.3
53/1.8
64/2.4
49/1.8
74/0 9
72/0.5
87/1.3
81/1.2
54/1.5
81/0.7
52/0.8
Recovery (%)
After
CD34-
selection
45
36
70
50
64
29
19
61
42
31
21
After
purging
36
18
43
39
25
28
17
43
18
15
15
CD34+
cells/kg
after CD34-
selection
and purging
1.3 x 10*
1.2 x 10*
2.2 x 10*
1.0 x 10*
0.8 x 10*
0.8 x 10*
1.5 x 10*
1.7 x 10*
1.2 x 10*
1.0 x 10*
0.6 x 10*
Recovery was calculated as 100% x (MNC after CD34-selection or
purging x % CD34+ cells)/(MNC before CD34-selection x % CD34+
cells).
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moAbs only, because GMP grade anti-CDIO antibodies
were not available at the time of their harvest. The mean
number of mononuclear cells loaded on the column was
340 x 108 (range 110-870 x 108) containing a mean of
1.7% (range 0.2%-4.5%) CD34+ cells. The mean num-
ber of CD34+ cells recovered after the column separa-
tion was 43% (range 19%-70%). CD34-selection and
immunomagnetic purging reduced mononuclear cells to
a mean of 1.3 x 108 (range 0.5-2.4 x 108) and enriched
CD34+ cells to a mean of 68% (range 49%-87%). The
mean number of CD34+ cells recovered after CD34-
selection and immunomagnetic purging was 27% (range
15%-43%). The mean number of retransfused CD34+
cells per patient after CD34-selection and immunomag-
netic purging was 1.2 x 106/kg body weight (range 0.6-
2.2 x 106/kg body weight).
Safety data
All patients received high-dose chemotherapy with cyclo-
phosphamide, BCNU and etoposide. Three days after
completion of chemotherapy, cryopreserved and immu-
nopurged cells fractions were thawed and retransfused.
The Kaplan-Meier estimate of the median time to neu-
trophil recovery to > 0.5 x 1O9/1 calculated from the day
of retransfusion was 10 days for the eight patients receiv-
ing > 1 x 106 CD34+ cells/kg body weight and 11 days
for the three patients receiving < 1 x 106 CD34+ cells/
kg body weight as shown in Figure 2A. The Kaplan-
Meier estimate of the median time to platelet recovery to
> 50 x 1O9/1 calculated from the day of retransfusion
was 16 days for the eight patients receiving > 1 x 106
CD34+ cells/kg body weight and 17 days for the three
patients receiving < 1 x 106 CD34+ cells/kg body weight
as shown in Figure 2B. Patients received a mean number
of 2 (range 1-3) platelet transfusions and a mean num-
ber of 3 (range 2-8) packed red blood cell transfusions.
Mean inpatient days were 22 (range 19-26) and mean
days of i.v. antibiotics and antivirals were 8 (range 0-14)
and three days (0-8) respectively. Major toxicity con-
sisted in four septicemias {Pseudomonas aeruginosa,
Escherichia coli, Staphylococcus aureus and Strepto-
coccus mitis). Localized herpes simplex infections were
treated with i.v. acyclovir in five patients.
Discussion
In this study we report the feasability and safety of a
positive selection of CD34+ cells followed by a negative
selection with immunomagnetic purging with anti-B-
cell moAbs in 11 patients with B-cell non-Hodgkin's
lymphomas undergoing high-dose therapy with retrans-
fusion of autologous HPC's.
Our major concern was that the combination of
CD34-selection with immunomagnetic purging would
result in an insufficient yield of CD34+ cells impairing
hematologic recovery after high dose therapy. The loss
of CD34+ cells was considerable, with a mean recovery
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Days after retransfusion of CD34-
selected and immunopurged HPC's
Figure 1 (a) Kaplan-Meier analysis of time to neutrophil count
recovery of 0.5 x 109/l and (b) Kaplan-Meier analysis of time to
platelet count recovery of 50 x 109/l. (—), > 1 x 106 CD34+ cells/kg
body weight, ( - - - ) ,< 1 x 106 CD34+ cells/kg body weight.
of only 27% (range 19%-70%) after CD34-selection and
immunomagnetic purging, resulting in less than 1 x 106
CD34+ cells/kg/body weight in three patients. Never-
theless, engraftment was rapid with a median of 11 days
to neutrophil recovery of > 5 x 109/l and a median of
17 days to platelet recovery of > 50 x 109/l; a result
comparable to our previous studies using unmanipu-
lated bone marrow [11, 12], or other studies using
CD34-selected mobilized peripheral blood HPC's [6-8].
As shown in Figure 2, neutrophil and platelet recovery
was not significantly different between patients retrans-
fused with > 1 x 106 CD34+ cells/kg body weight and
< 1 x 106 CD34+ cells/kg body weight. With 82% neu-
tropenic fever and 36% microbiologically documented
infections, the rate of complications was comparable to
our previous experience with unprocessed bone marrow
cells [11, 15]. No late infections have been observed in
our short follow up period of 8.3 months (range 1-19
months).
Our mean purity and recovery of 68% (range 49%-
87%) and 43% (range 19%-70%) CD34+ cells respec-
tively, after passage over the Ceprate SC Stem Cell Con-
centrator are comparable to published reports using the
same cell separator to enrich CD34+ cells from bone
marrow or mobilized peripheral blood HPC harvests [7,
8]. In contrast, other CD34+ cell sorting systems such as
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the Baxter Isolex 300 magnetic cell separation system
[13] or the Super MACS high gradient magnetic cell
sorting system [14] have been reported to achieve mean
yields of more than 90% CD34+ cells from mobilized
peripheral blood HPC harvests. Therefore, we intend to
evaluate the efficacy of the Baxter Isolex 300 magnetic
cell separation system for our further studies. Moreover,
samples of apheresis products as well as the CD34-
selected and immunomagnetically purged cell fractions
were collected to assess purging efficacy by PCR analy-
sis for the presence of t(14;18)+ or lymphoma specific
IgH CDRIII sequence carrying cells. Results will be
reported at a later timepoint.
In conclusion, the retransfusion of CD34-selected
and immunomagnetically purged HPC's is safe and
mediates rapid hematological recovery after high dose
therapy for B-cell lymphomas.
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